Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.

ABSTRACT:

Background

Successful preventive therapy for ischemic priapism, a disorder of penile erection with major physical and psychologic consequences, is limited. We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of sildenafil by a systematic dosing protocol to prevent recurrent ischemic priapism associated with sickle cell disease.

Methods

Thirteen patients with sickle cell disease reporting priapism recurrences at least twice weekly were randomized to receive sildenafil 50 mg or placebo daily, unassociated with sleep or sexual activity, for 8 weeks, followed by open-label use of this sildenafil regimen for an additional 8 weeks.

Results

Priapism frequency reduction by 50% did not differ between sildenafil and place

SUBMITTER: Burnett AL 

PROVIDER: S-EPMC4085689 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature